Definitions
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun A benzoporphyrin
derivative used as aphotosensitizer forphotodynamic therapy to eliminate the abnormalblood vessels in the eye associated with conditions such as the wet form of macular degeneration.
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word verteporfin.
Examples
-
They trapped a photosensitive drug called verteporfin, which creates toxic oxygen radicals when exposed to specific wavelengths of light, inside solid polymer nanoparticles.
-
Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
-
Patients were randomized to one of three monthly treatments for two years: 0.3 mg (137 patients) or 0.5 mg (139 patients) of intravitreal ranibizumab plus sham photodynamic therapy or active verteporfin photodynamic therapy plus sham injections (142 patients).
MedPageToday.com - medical news plus CME for physicians 2009
-
Other components examine a lower dose of verteporfin and use in polypoidal choroidal vasculopathy.
MedPageToday.com - medical news plus CME for physicians 2009
-
The researchers noted that this is the first wave of results from the SUMMIT clinical trial program of verteporfin combination therapy.
MedPageToday.com - medical news plus CME for physicians 2009
-
BALTIMORE, Jan. 16 -- For patients with neovascular age-related macular degeneration, ranibizumab (Lucentis) outperformed photodynamic therapy with verteporfin (Visudyne) in a phase III trial.
MedPageToday.com - medical news plus CME for physicians 2009
-
EUS-guided photodynamic therapy with verteporfin for ablation of normal pancreatic tissue: a pilot study in a porcine model (with video).
-
EUS-guided photodynamic therapy with verteporfin for ablation of normal pancreatic tissue: a pilot study in a porcine model (with video).
-
Kaiser PK, Michels M, Soubrane G, Heier JS, et al. (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
PLoS ONE Alerts: New Articles Magali Saint-Geniez et al. 2008
-
Visual acuity after 12 months of verteporfin (Visudyne) plus ranibizumab (Lucentis) was statistically noninferior to ranibizumab monotherapy (
MedPageToday.com - medical news plus CME for physicians 2009
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.